Are law-breaking pharma executives the new mob bosses? Can genome editing prevent heart attacks? And can the FDA regulate drug prices?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Ed Silverman joins us to discuss how the recent convictions of executives at Insys Therapeutics could shape the way drug companies are held accountable for misdeeds. Then, we break down a curious drug approval that will break up a rare disease monopoly. Finally, STAT’s Sharon Begley stops by to explain an audacious startup’s plan to take CRISPR from niche uses to the medical mainstream.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy